HBOT Conversations:
Dr. Paul Harch & 8,101 Genes
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on 8,101 genes is the eighth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
In episode 8 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch, about aging and the 8,101 genes HBOT affects.
di Girolamo starts this conversation with Dr. Harch bringing up the 8,101 genes that are activated by Hyperbaric Oxygen Therapy. The discussion leads to talk of Big Pharma, telomeres, reparative gene process, patents, and successful business models for HBOT clinics.
Dr. Harch explains that Hyperbaric Oxygen Therapy affects 8,101 of our genes, and it’s doing so on a different level for the ones that are overactive and abnormal in the disease process. He speaks of a 2004 lecture he gave to A4M about the effects of HBOT on longevity; and asks, “Where is senescence and aging based?”, answering with, “It’s in our DNA”. Dr. Harch dives in to how HBOT turns on our genes to grow new tissue and stimulates cellular repair and regeneration. di Girolamo agrees and brings up a different past lecture from Dr. Harch where Harch referred to Hyperbaric Oxygen Therapy as the ‘Fountain of Youth‘.
This series ends with Dr. Harch discussing a Buffalo VA study, and how the study subjects (comprised of older veterans) literally came alive and started propositioning nurses after Hyperbaric Oxygen Therapy treatments. He explained this is why no follow-up study was ever done because they weren’t expecting such and didn’t know what to do. Makes sense…. studies have shown success in HBOT treating erectile dysfunction.
If you are searching for the Fountain of Youth and ready to activate 8,101 genes in your body —- find a Hyperbaric Oxygen Therapy clinic near you.
Subscribe Now, It’s Free!
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Changes in vasomotion–effect of hyperbaric oxygen in patients with diabetes Type 2.
Abstract: To investigate vasomotion in diabetic patients who underwent sessions of hyperbaric oxygen (HBO2) therapy. Seventy-one patients with diabetes Type 2 and lower-extremity neuropathy were enrolled in a prospective matched case-control study. A total of 39...
Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?
Abstract: Tumor hypoxia is a major cause for failure of therapy in patients with inoperable head and neck cancers. Various anti-hypoxic treatment strategies (e.g. hyperbaric oxygenation, hypoxic cell sensitizers) have been tested in clinical trials in head and neck...
Clinical Trial – Ondansetron vs Ondansetron Plus Dexamethasone for Relieving Intrathecal Morphine Side Effects After C-section
Background: Common adverse side effects related to the use of neuraxial opioids in the
obstetric population include nausea, vomiting, and pruritus. Serotonin (5-HT3) receptor
antagonists, in particular ondansetron, have been identified as possible antipruritic agents.
It was reported that dexamethasone plus ondansetron is more effective than ondansetron for
prevention of postoperative nausea and vomiting but no additional effect on treating
pruritus.
Objectives: The purpose of this study is to compare the effect of prophylactic ondansetron
versus ondansetron plus dexamethasone after cesarean section on pruritus and postoperative
nausea and vomiting (PONV).
Methods: A prospective randomized double blind study that will be conducted between June 2016
and June 2017. Patients will be randomly allocated into two groups. The first group will
receive 4 mg intravenous (IV) ondansetron while the other group will receive 4 mg IV
ondansetron plus 8 mg dexamethasone.